Looking Past Aduhelm, Biogen Puts Pipeline On Display

Biogen, Inc. is keen to show that it has more in its research and development pipeline than its newly approved Alzheimer’s drug Aduhelm (aducanumab), which is struggling to meet even conservative early sales expectations, so the company hosted an R&D Day to showcase its 33 early through late-stage clinical programs for investors. The pipeline will yield clinical trial results between fall 2021 and late 2022 for five drug candidates from two proof-of-concept studies and four Phase III trials.

Those readouts will come from drugs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), depression and schizophrenia. Many depend on genetic causes of disease or other biomarkers as part of Biogen’s...